Aspen is well positioned in both developing and developed markets – it is the largest pharmaceutical company in Africa, and has an expanding presence in Latin America, Asia, Europe and the Commonwealth of Independent States, comprising Russia and the former Soviet Republics (“CIS”). Aspen is also one of the leading pharmaceutical companies in Australia and is establishing a presence in other developed markets such as the United States of America (“USA”) and Canada.
With an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced throughout all stages of life, Aspen continues to increase the number of lives benefiting from its products, reaching more than 150 countries across the world.
Aspen's results for the year ended 30 June 2017 were announced at a presentation and webcast on Thursday, 14 September 2017.
The presentation is available for download here and on the home page of this website.
Strong market position
Diversified geographies and product offering
Proven track record
Leverages on local knowledge and expertise
Centralised Group activities facilitate synergies and mitigate pricing pressures
Positive growth drivers
Responsible corporate citizen
30 June 2017
Financial year end.
14 September 2017
Year end results announcement, presentation and webcast at the JSE, Johannesburg.
Click here for the results presentation.
Publishing of the Integrated Report.
7 December 2017
Annual General Meeting.
SHARE PRICE CENTRE
View share price information for Aspen Holdings.
APN ISIN: ZAE 000066692
JSE data delayed by 15 minutes, page refreshes every 5 minutes. Indicated trade times are actual.
Delivering double-digit earnings growth to our shareholders for 17 consecutive years
Analysis of shareholders at 30 June 2016
All corporate information and contact details